Potent agonists of growth hormone‐releasing hormone: Part I

MARTA ZARANDI, PETER SERFOZO, JOZSEF ZSIGO, LAZARO BOKSER, TAMAS JANAKY, DONALD B. OLSEN, SANDOR BAJUSZ, ANDREW V. SCHALLY

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Analogs of the 29 amino acid sequence of growth hormone-releasing hormone (GH-RH) with agmatine (Agm) in position 29 have been synthesized by the solid phase method, purified, and tested in vitro and in vivo. The majority of the analogs contained desaminotyrosine (Dat) in position 1, but a few of them had Tyr1, or N-MeTyr1. Some peptides contained one or more additional L- or D-amino acid substitutions in positions 2, 12, 15, 21, 27, and/or 28. Compared to the natural sequence of GH-RH(1-29)NH2,[Dat1,Ala15]GH-RH(1-28)Agm (MZ-3-191) and [D-Ala2,Ala15]GH-RH(1-28)Agm (MZ-3-201) were 8.2 and 7.1 times more potent in vitro, respectively. These two peptides contained Met27. Their Nle27 analogs, [Dat1,Ala15,Nle27]GH-RH(1-28)Agm (MZ-2-51), prepared previously (9), and [D-Ala2,Ala15,Nle28]GH-RH(1-28)Agm (MZ-3-195) showed relative in vitro potencies of 10.5 and 2.4, respectively. These data indicate that replacement of Met27 by Nle27 enhanced the GH-releasing activity of the analog when the molecule contained Dat1-Ala2 residues at the N-terminus, but peptides containing Tyr1-D-Ala2 in addition to Nle27 showed decreased potencies. Replacement of Ser28 with Asp in multi-substituted analogs of GH-RH(1-28)Agm resulted in a decrease in in vitro potencies compared to the parent compound. Thus, the Ser28-containing MZ-2-51, and [Dat1-Ala15,D-Lys21,Nle27]GH-RH(1-28)Agm, its Asp28 homolog (MZ-3-149), possessed relative activities of 10.5 and 5.6, respectively. In vivo after the iv injection, the analogs [Dat1,Ala15,Nle27,Asp28]GH-RH(1-28)Agm (MZ-3-149), [Dat1,Ala15]GH-RH(1-28)Agm, (MZ-3-191) and [D-Ala2,Ala15]GH-RH(1-28)Agm (MZ-3-201) showed a potency equivalent to 7.6, 4.9 and 3.3 times that of GH-RH(1-29)NH2, respectively, at 5 min and 203, 4.3 and 1.7 times higher, respectively, at 15 min. After sc administration, analogs MZ-3-149, MZ-3-191, and MZ-3-201 were shown to be 63.7, 55.2 and 56.8 times more potent than the parent hormone at 15 min and 57.6, 60.6, and 42.6 times more active, respectively, at 30 min. In addition, MZ-3-149 had prolonged GH-releasing activity as compared to the standard, and proved to be more potent than MZ-2-51, the most active member of our previous series (8, 9). Our studies indicate that very potent GH-RH analogs can result from the combination of agmatine in position 29 with other substitutions.

Original languageEnglish (US)
Pages (from-to)211-217
Number of pages7
JournalInternational journal of peptide and protein research
Volume39
Issue number3
DOIs
StatePublished - Mar 1992
Externally publishedYes

Keywords

  • GH‐RH analogs
  • growth hormone‐releasing hormone
  • solid phase peptide synthesis
  • structure‐activity relationships

ASJC Scopus subject areas

  • Biochemistry

Fingerprint Dive into the research topics of 'Potent agonists of growth hormone‐releasing hormone: Part I'. Together they form a unique fingerprint.

  • Cite this

    ZARANDI, MARTA., SERFOZO, PETER., ZSIGO, JOZSEF., BOKSER, LAZARO., JANAKY, TAMAS., OLSEN, DONALD. B., BAJUSZ, SANDOR., & SCHALLY, ANDREW. V. (1992). Potent agonists of growth hormone‐releasing hormone: Part I. International journal of peptide and protein research, 39(3), 211-217. https://doi.org/10.1111/j.1399-3011.1992.tb00791.x